Understanding the Unique Role of HER3 in Oncogenesis

Access Activity

Overview / Abstract:

Target Audience
This activity is designed to meet the educational needs of academic and community oncologists, along with other providers who assist in the management of non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC), and other solid tumor cancer patients.

Program Overview
This activity will explore the clinical evidence surrounding the role of HER3 in various tumor types.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Recognize the role of the HER family, and particularly HER3, in oncogenesis
Identify the common causes of disease progression in patients with advanced NSCLC, metastatic breast, and other solid tumor cancers, focusing specifically on treatment failure to epidermal growth factor receptor or anti-estrogen-based therapies
Explain the mechanism of disease of HER3 and HER3-directed antibody drug conjugates (ADCs) under investigation for the treatment of EGFR TKI-resistant NSCLC, breast, and other solid tumor cancers

Expiration

Mar 07, 2023

Discipline(s)

Physician CME

Format

Online

Credits / Hours

0.75

Accreditation

ACCME, ANCC, ACPE

Presenters / Authors / Faculty

Joan T. Garrett, PhD

Sponsors / Supporters / Grant Providers

Daiichi Sankyo, Inc

Keywords / Search Terms

Relias LLC Relias, Free CME, HER3, Cancer Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map